Journal of Clinical Pharmacology

Article	Citations
	94
	60
Protecting Mothers and Babies Through Research	42
Incidence of Antiseizure Medication–Induced Severe Cutaneous Adverse Reactions in Malaysia	33
Assessment of the Effect of Organ Impairment on the Pharmacokinetics of 2′‐MOE and Phosphorothioate Modified Antisense Oligonucleotides	30
Influence of Renal Function on Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Romosozumab	30
Low Early Antifactor Xa Target Achievement Rate of Low‐Molecular‐Weight Heparin for Treating Venous Thromboembolism in Patients in Intensive Care	29
Maternal–Fetal Drug Development: An Industry Perspective	26
Clinical Lactation Studies of Neuropsychiatric Medications: Clinical Pharmacology and Labeling Considerations	24
Vancomycin Associated Purpuric Symmetrical Drug‐Related Intertriginous and Flexural Exanthema: A Rare Association and an Uncommon Presentation	24
Efanesoctocog Alfa Population Pharmacokinetics and Repeated Time‐To‐Event Analysis of Bleeds in Adults, Adolescents, and Children with Severe Hemophilia A	23
Issue Information	21
Exploring Factors Affecting the Occurrence of Hypersensitivity Reactions Induced by Nonionic Iodine Contrast Media	20
Reassessing the Pediatric Dosing Recommendations for Unfractionated Heparin Using Real‐World Data: A Pharmacokinetic–Pharmacodynamic Modeling Approach	18
What Is the Role of Sex‐Related Differences in the Effectiveness and Safety of Biological Drugs Used in Patients With Severe Asthma?	18
Development and Verification of a Japanese Pediatric Physiologically Based Pharmacokinetic Model with Emphasis on Drugs Eliminated by Cytochrome P450 or Renal Excretion	18
Thyroid Antibody Titers and Hypothalamic‐Pituitary‐Thyroid Axis Activity in Levothyroxine‐Treated Women With Autoimmune Subclinical Hypothyroidism Receiving Atorvastatin or Metformin	18
	18
Challenges in Conducting Therapeutic Trials in Pregnancy: Emphasizing Recent Lessons Learned	18
In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug Transporters	17
Methoxyethyl Etomidate Hydrochloride (ET‐26): A Phase I Clinical Trial Assessing Drug–Drug Interactions in Healthy Subjects	17
Association Between the Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Drug‐Induced Acute Kidney Injury: Analysis of 2 Databases	17
Safety, Pharmacokinetics, and Pharmacodynamics of the New Aldose Reductase Inhibitor Govorestat (AT‐007) After a Single and Multiple Doses in Participants in a Phase 1/2 Study	17
Pharmacokinetics and Safety of a Novel Extended‐Release Microsphere Formulation of Risperidone in Patients with Schizophrenia or Schizoaffective Disorder	17
Issue Information	17

Comment: Cerebrospinal Fluid Pharmacokinetics of Nicardipine Following Intrathecal Administration in Subarachnoid Hemorrhage Patients	16
Issue Information	16
Exposure‐Response Relationships for Pralsetinib in Patients with RET‐Altered Thyroid Cancer or RET Fusion‐Positive Nonsmall Cell Lung Cancer	15
	15
Is There a Need for a Dedicated Pharmacokinetic Trial for a Drug in Obese Populations? A Drug Prioritization Decision Tree Framework	15
Guiding Dyslipidemia Treatment: A Population Pharmacokinetic–Pharmacodynamic Framework for Obicetrapib	15
Determination of Vatiquinone Drug‐Drug Interactions, as CYP450 Perpetrator and Victim, Using Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation	15
Population Pharmacokinetic Simulations for Dose Optimization of Tenofovir Disoproxil Fumarate in HIV‐Infected Patients with Moderate‐to‐Severe Renal Impairment	15
Off‐Label Use of Hydroxychloroquine in COVID‐19: Analysis of Reports of Suspected Adverse Reactions From the Italian National Network of Pharmacovigilance	15
Impact of Pregnancy and Vitamin A Supplementation on CYP2D6 Activity	15
Comparison of Misoprostol and Evening Primrose Oil on Cervical Preparation Before Gynecological Surgery	14
The Role of the Mesencephalic Astrocyte‐Derived Neurotrophic Factor in Patients in Intensive Care Units Receiving Voriconazole Therapy	14
Population Pharmacokinetics of Sertraline in Psychiatric and Substance Use Disorders	14
Using Real‐World Data to Externally Evaluate Population Pharmacokinetic Models of Dexmedetomidine in Children and Infants	14
Population Pharmacokinetics of Ranibizumab Delivered via the Port Delivery System Implanted in the Eye in Patients with Neovascular Age‐Related Macular Degeneration	14
Investigation of the Effect of Lasmiditan on the Pharmacokinetics of P‐Glycoprotein and Breast Cancer Resistance Protein Substrates	14
Contemporary Use of Oral Inotropes in the Outpatient Treatment of Heart Failure: Analysis of a Japanese Nationwide Database	13
Pharmacokinetic and Pharmacodynamic Modeling Analysis of Delpazolid (LCB01‐0371) in Adult Patients with Pulmonary Tuberculosis	13
	12
Issue Information	12
Physiologically based Pharmacokinetic/Pharmacodynamic Modeling (PBPK/PD) of Famotidine in Pregnancy	12
Back Pedaling on Baclofen: Highlighting Concerns Surrounding Baclofen use in Phenibut Withdrawal	12
Pharmacokinetics of Antiretroviral Agents in Pregnant Individuals Living With HIV: Current Status and Considerations for Study Design and Interpretation	12
Effectiveness and Safety of Histamine H2 Receptor Antagonists: An Umbrella Review of Meta‐Analyses	12
Disproportionality Analysis of Intravitreal Ranibizumab, Aflibercept, and Brolucizumab for Cardiovascular and Cerebrovascular Events	12
Characterizing Associations of QTc Interval with Nocturnal Glycemic Control in Children with Type 1 Diabetes	12
Comparison of Two Dexmedetomidine Administration Strategies on the Incidence of Postoperative Respiratory Complications: A Retrospective, Inverse Probability of Treatment Weighted Study	12
A Phase I Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Liposomal Bupivacaine for Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy	12
Pooled Population Pharmacokinetic Analyses of Venetoclax in Patients Across Indications and Healthy Subjects from Phase 1, 2, and 3 Clinical Trials	12
Will the Pharmacologically Meaningful Half‐Life Please Stand Up?	12
Clinical Consequences of Altered Drug Disposition in Obesity: Call for Change	12
A Phase 1 Randomized Study: Garadacimab Pharmacokinetics, Safety, and Tolerability After Administration via Autoinjector/Pre‐Filled Pen Versus Pre‐Filled Syringe in Healthy Participants	11
Issue Information	11
In Vitro and Clinical Evaluations of UGT1A1‐, P‐gp‐, OATP1B1‐, and BCRP‐Mediated Drug–Drug Interactions of Belumosudil, a Potent ROCK2 Inhibitor	11
Exposure‐Efficacy Analysis and Dopamine D2 Receptor Occupancy in Adults with Schizophrenia after Treatment with the Monthly Intramuscular Injectable Risperidone ISM	11
Efficacy and Safety of Oral Semaglutide in the Treatment of Type 2 Diabetes: A Meta‐Analysis	10
Antidepressants and Antipsychotics in Human Pregnancy: Transfer Across the Placenta and Opportunities for Modeling Studies	10
Addressing Drug–Drug Interaction Knowledge Gaps at the Time of Approval: An Analysis of FDA Postmarketing Requirements and Commitments from 2009 to 2023	10
Daptomycin Dose Optimization in Pediatric Staphylococcus aureus Bacteremia: A Pharmacokinetic/Pharmacodynamic Investigation	10
A Retrospective Cohort Study Examining the Effects of Anti‐PD‐1 Antibody in Combination with Apatinib in Patients Previously Treated for Her2‐Negative Advanced Gastric/Gastroesophageal Junction Cancer	10
Physiologically Based Pharmacokinetic (PBPK) Model to Predict the Magnitude of Drug–Drug Interaction Between Fezolinetant and CYP1A2 Inhibitors	10
Issue Information	10
Development and Evaluation of Ontogeny Functions of the Major UDP‐Glucuronosyltransferase Enzymes to Underwrite Physiologically Based Pharmacokinetic Modeling in Pediatric Populations	9
Understanding and Streamlining Dose Finding: From Dose Simulation to Dose Estimation	9
Risk of Pregabalin‐Induced Hypoglycemia: Analysis of the Japanese Adverse Drug Event Report Database	9
An Investigation in the Comparability of the Exposure and Recommended Dose of Selected Pfizer Drugs in East Asian Countries: Is Mutual Usage of Clinical Data Among East Asian Countries Feasible?	9
Inclisiran: A Novel Small Interfering RNA Drug for Low‐Density Lipoprotein Reduction	9
Regulatory Framework for Drug Development in Rare Diseases	9
Ensuring the Appropriate Use of Glucagon‐Like Peptide‐1 Receptor Agonists	9
JCP 2022 Reviewer Thank‐You List	8

Population Pharmacokinetic Modeling of Adavosertib (AZD1775) in Patients with Solid Tumors	8
Influence of Calcineurin Inhibitors and Genetic Polymorphism of Transporters on Enterohepatic Circulation and Exposure of Mycophenolic Acid in Chinese Adult Renal Allograft Recipients	8
Issue Information	8
Efficacy of Bile Acid Sequestrants in the Treatment of Bile Acid Diarrhea: A Meta‐Analysis of Randomized Controlled Trials	8
Population Pharmacokinetics of Hydroxychloroquine Sulfate in Healthcare Workers, Given for Prophylaxis Against Coronavirus Disease 2019 (COVID‐19) in India	8
Expansion of a Pharmacokinetic Model for Diazepam to Characterize Real‐World IV and Oral Data in Children With and Without Obesity	8
Physiologically Based Pharmacokinetic Modeling for Maribavir to Inform Dosing in Drug‐Drug Interaction Scenarios with CYP3A4 Inducers and Inhibitors	8
Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus	8
Quantitative Comparison of the Predictive Accuracy of Warfarin Pharmacogenetic Dosing Algorithms Derived From Population Data of Different Ethnicities in the Chinese Population	8
Characterization of Immune Checkpoint Inhibitor–Induced Myasthenia Gravis Using the US Food and Drug Administration Adverse Event Reporting System	8
Drug–Drug Interaction Potential of Mavacamten with Midazolam: Combined Results from Clinical and Model‐Based Studies	8
Influence of Dapagliflozin Dosing on Low‐Density Lipoprotein Cholesterol in Type 2 Diabetes Mellitus: A Systematic Literature Review and Meta‐Analysis	8
	8
Clinical Pharmacology Considerations on Recombinant Adeno‐Associated Virus–Based Gene Therapy	8
Correction to “The Association Between Concurrence of Infection and the Onset of Severe Eruption or Liver Injury in Patients Using Antipyretic Analgesics: A Matched, Nested Case‐Control Study”	8
In Silico Modeling for Ex Vivo Placental Transfer of Morphine	8
The Impact of Standard Versus Weight‐Based Maintenance Dosing of Fosphenytoin on Achieving Therapeutic Drug Levels	8
2023 JCP Peer Reviewer List	8
Optimization of Voriconazole Dosing Regimens Against Aspergillus Species and Candida Species in Pediatric Patients After Hematopoietic Cell Transplantation: A Theoretical Study Based on	8
Capillary Filtration of Plasma Is Accelerated During General Anesthesia: A Secondary Population Volume Kinetic Analysis	8
Direct Oral Anticoagulants: An Updated Systematic Review of Their Clinical Pharmacology and Clinical Effectiveness and Safety in Patients With Nonvalvular Atrial Fibrillation	8
Population Pharmacokinetics and Exposure–Response Analysis of Tremelimumab 300 mg Single Dose Combined with Durvalumab 1500 mg Q4W (STRIDE) in Patients with Unresectable Hepatocellular Carcinoma	7
Missed Opportunities: Intravenous versus Oral Antibiotic De‐escalation for Treatment of Lower Extremity Osteoarticular Infections	7
Pharmacokinetics and Metabolism of Melflufen, an Alkylating Peptide–Drug Conjugate, in Patients with Relapsed Refractory Multiple Myeloma	7
Exposure–Response Analyses of Polysomnography and Subjective Sleep Efficacy End Points From the Phase 3 Trials of Lemborexant, a Dual Orexin Receptor Antagonist for the Treatment of Insomnia	7
Once‐ Versus Twice‐Daily Tacrolimus Therapy: Does Improved Adherence Lead to Better Efficacy?—A Pharmacokinetic Perspective	7
Issue Information	7
Clinical Pharmacology Guidances Advancing Drug Development and Regulatory Assessment: Role and Opportunities	7
Evaluation of Preoperative Risk Factors for Sugammadex‐Induced Anaphylaxis: Analysis of the Japanese Adverse Drug Event Report Database	7
Evaluation of the Efficacy of Dexmedetomidine as a Local Anesthetic Adjuvant in Children: A Meta‐Analysis of Randomized Controlled Trials	7
Preclinical and Clinical Pharmacokinetics of JNJ‐75220795, an siRNA Therapeutic Targeting PNPLA3, for Metabolic Dysfunction‐Associated Steatohepatitis	7
	7
	7
Population Pharmacokinetics and Exposure‐Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light‐Chain Amyloidosis	7
Precision Pharmacokinetics of Quetiapine: A Physiologically Based Model Incorporating Liver Cirrhosis and CYP3A4 Polymorphisms	7
Five‐Year Outcomes of Continuous Treatment with Zoledronic Acid Versus Denosumab in Older Men with High Fracture Risk: Risk Factor Analysis of Bone Density Improvement and Incidence of New Fracture	7
Influence of Disease Type and Activity on Adalimumab Exposure in Children with Inflammatory Rheumatic Diseases	7
Reply to: Comment: Cerebrospinal Fluid Pharmacokinetics of Nicardipine Following Intrathecal Administration in Subarachnoid Hemorrhage Patients	7
Immunogenicity of Cemiplimab: Low Incidence of Antidrug Antibodies and Cut‐Point Suitability Across Tumor Types	7
Drug Interactions With a Short Course of Nirmatrelvir and Ritonavir: Prescribers and Patients Beware	7
Practical Applications of a Nausea and Vomiting Model in the Clinical Development of Additional Doses of Dulaglutide	7
An Intravenous Study with the Radiolabeled sGC Stimulator Frespaciguat to Assess PK, Metabolism, and Mass Balance	6
Vaginal Misoprostol Pharmacokinetic Changes in Obese Parturient Women Who Presented Labor Induction Failure	6
Physiologically Based Pharmacokinetic Modeling of Metformin in Children and Adolescents With Obesity	6
US FDA Postmarketing Requirements and Commitments: A Systematic Assessment of Clinical Pharmacology Studies and Their Impact on US FDA Prescribing Information	6
Gastrointestinal Bleeding During Direct Oral Anticoagulant Therapy in Patients With Nonvalvular Atrial Fibrillation and Risk of Polypharmacy	6
In Memoriam: Varsha Bhatt‐Mehta, PharmD, MS, FCCP	6
Predicted Cardiac Functional Responses to Renal Actions of SGLT2i in the DAPACARD Trial Population: A Mathematical Modeling Analysis	6
Limited Sampling Strategy for Predicting the Area under Plasma Concentration–Time Curve of Nadolol in Healthy Subjects	6
Modification of Vancomycin Dosing in Cardiac Surgery With Cardiopulmonary Bypass	6
	6
Over‐the‐Counter Epinephrine for Asthma Treatment: Too Much Risk for Too Little Benefit	6
Street Pharmacology: Toxico‐Dermatology of Injection Drug Use	6
Extension of the Alternative Intravenous Dosing Regimens of Atezolizumab into Combination Settings through Modeling and Simulation	6
	6
Population Pharmacokinetics of Ponatinib in Healthy Adult Volunteers and Patients With Hematologic Malignancies and Model‐Informed Dose Selection for Pediatric Development	6
Genetic Polymorphism as a Possible Cause of Severe Postoperative Pain	6
Population Pharmacokinetics (PopPK) Support for Pediatric Dosing of Biological Products	6
Issue Information	6
Pediatric Population Pharmacokinetic Modeling and Exposure–Response Analysis of Ambrisentan in Pulmonary Arterial Hypertension and Comparison With Adult Data	6
Issue Information	6
Comparison of the Treatment Persistence Among 4 Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: A 5‐Year Retrospective Cohort Study	6
Efficacy and Safety of Adjunctive Serotonin‐Dopamine Activity Modulators in Major Depression: A Meta‐Analysis of Randomized Controlled Trials	6
Pharmacokinetics and Safety of Fenofibrate in Participants with Mild Hepatic Impairment or with Advanced Fibrosis due to Metabolic‐Associated Fatty Liver Disease	6
Issue Information	6
Issue Information	6
	6
Physiologically Based Pharmacokinetic Modeling of Vancomycin in Critically Ill Neonates: Assessing the Impact of Pathophysiological Changes	6
Issue Information	6
Clinical Pharmacokinetics From the Beginning: A Practical Approach	6
Effect of Food on the Pharmacokinetics, Safety, and Tolerability of Budesonide Oral Suspension in Healthy Adult Participants: A Randomized Phase 1 Study	6
Effects of Renal Impairment on the Pharmacokinetics of Gefapixant, a P2X3 Receptor Antagonist	6
Evaluation of Cannabis Per Se Laws: A Semi‐Mechanistic Pharmacometrics Model for Quantitative Characterization of THC and Metabolites in Oral Users	6
Issue Information	6
Physiologically Based Pharmacokinetic Modeling of Lemborexant: Exploration of Doses for Populations with Hepatic Impairment	6
In Silico Re‐Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure–Response Simulation	6
Study of the Association of Single Nucleotide Polymorphisms in Candidate Genes With Sevoflurane	6
Issue Information	6
Population Pharmacokinetics of Nirsevimab in Preterm and Term Infants	6
Myelosuppression Caused by Nanoparticle Albumin‐Bound Paclitaxel in the Northern Chinese Population and the Role of Body Composition	6

From Genotype to Therapeutic Monitoring: Enhancing Tamoxifen Efficacy in Breast Cancer Treatment	6
	6
Changing Trajectories of Alanine Aminotransferase and Risk of Antituberculosis Drug‐Induced Liver Injury in Chinese Patients: A Cohort Study	6
Association of Gene Polymorphisms and Serum Levels of ALAS1 with the Risk of Anti‐Tuberculosis Drug‐Induced Liver Injury	5
In Vitro Evaluation of CYP‐Mediated Metabolism of Fezolinetant and Pharmacokinetic Interaction Between Fezolinetant and Fluvoxamine in Healthy Postmenopausal Smokers and Nonsmokers	5
Evaluation of Drug‐Drug Interactions of Ensitrelvir, a SARS‐CoV‐2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies	5
Comparison of Clinical Effectiveness Between Ambroxol and N‐Acetylcysteine in Surgical Patients: A Retrospective Cohort Study	5
A Retrospective Analysis of Intravenous vs Oral Antibiotic Step‐Down Therapy for the Treatment of Uncomplicated Streptococcal Bloodstream Infections	5
Application of a Precision‐Dosing Model to a Real‐World Cohort of Patients on Infliximab Maintenance Therapy: Drug Usage and Cost Analysis	5
A Retrospective Analysis of PK and Response of Oral Ibuprofen in the Treatment of a Patent Ductus Arteriosus in Extremely Low Gestational Age Neonates	5
Extrapolation of Adult Efficacy Data to Pediatric Systemic Lupus Erythematosus: Evaluating Similarities in Exposure–Response	5
The Impact of Survival Benefit and Study Design on FDA Approval for Anticancer Drugs Over the Past Decades	5
Novel Patient‐Friendly Orodispersible Formulation of Ivermectin is Associated With Enhanced Palatability, Controlled Absorption, and Less Variability: High Potential for Pediatric Use	5
Pharmacokinetics of Ipatasertib in Subjects With Hepatic Impairment Using 2 Methods of Classification of Hepatic Function	5
Neurological Immune‐Related Adverse Events After COVID‐19 Vaccination: A Systematic Review	5
Drug Combination Modeling: Methods and Applications in Drug Development	5
Autoimmune Thyroiditis Attenuates Cardiometabolic Effects of Cabergoline in Young Women With Hyperprolactinemia	5
Impact of Lisinopril on Cardiometabolic Risk Factors in Sisters of Women With Polycystic Ovary Syndrome	5
Intranasal Naloxone During Recurrent Exercise in Individuals with Type‐1 Diabetes Mellitus: Evaluation of the Clinical Predictors of Pharmacokinetics and Exposure–Response	5
Population Pharmacokinetics and Dose Simulation of Levetiracetam in Patients with Epilepsy: Influence of Renal Function and Phenytoin Co‐Administration	5
Population Pharmacokinetics of Valemetostat and Exposure–Response Analyses of Efficacy and Safety in Patients with Relapsed/Refractory Peripheral T–Cell Lymphoma	5
Quantitative Assessment of Drug Efficacy and Emergence of Resistance in Patients with Metastatic Renal Cell Carcinoma Using a Longitudinal Exposure‐Tumor Growth Inhibition Model: Apitolisib (Dual PI3K	5
	5
Conflation of Tuskegee Study With FDA Fiduciary Responsibilities Sensationally Ignores International Law	5
Population Pharmacokinetics of Caffeine in Infants with Hypoxic‐Ischemic Encephalopathy: A Phase I, Dose‐Escalating Trial	5
DOAC Dosing Discordance Using Different Estimates of Kidney Function and Outcomes	5
Predict the Drug–Drug Interaction of a Novel PI3Kα/δ Inhibitor, TQ‐B3525, and Its Two Metabolites Using Physiologically Based Pharmacokinetic Modeling	5
Drug‐Drug Interaction between Oral Zamicastat and Continuous Epoprostenol Infusion at Steady‐State Conditions in Healthy Subjects	5
The Role of Pain Medications in Modulating Peripheral Nerve Injury Recovery	5
Population Pharmacokinetic Model of Platinum Disposition in Cancer Patients Receiving Cisplatin and Randomized to 5‐HT3 Antagonist Antiemetic Drugs	5
Population Pharmacokinetic Modeling and Stochastic Simulations to Support Pediatric Dose Selection of Pimavanserin	4
Issue Information	4
Mechanistic Framework to Predict Maternal‐Placental‐Fetal Pharmacokinetics of Nifedipine Employing Physiologically Based Pharmacokinetic Modeling Approach	4
Infant Dextromethorphan and Dextrorphan Exposure via Breast Milk From Mothers Who Are CYP2D6 Extensive Metabolizers	4
In Memoriam	4
Statin Drug‐Drug Interactions: Pharmacokinetic Basis of FDA Labeling Recommendations and Comparison Across Common Tertiary Clinical Resources	4
Issue Information	4
Commentary on Pharmacologically Meaningful Half‐Life	4
Correlations of PCSK9 and LDLR Gene Polymorphisms and Serum PCSK9 Levels With Atherosclerosis and Lipid Metabolism in Patients on Maintenance Hemodialysis	4
Simultaneously Predicting Pharmacokinetics of Loratadine and Desloratadine in Children Using a Whole‐Body Physiologically Based Pharmacokinetic Model	4
Effects of Hepatic or Renal Impairment on Pharmacokinetics of Fruquintinib	4
Incidence of Adverse Events Induced by Atropine in Myopic Children: A Meta‐Analysis	4
Hypokalemia and Hyponatremia in Adult Patients Receiving Voriconazole Therapeutic Drug Monitoring	4
Clinical Assessment of the Drug–Drug Interaction Potential of Omaveloxolone in Healthy Adult Participants	4
Use of Propensity Scoring and Its Application to Real‐World Data: Advantages, Disadvantages, and Methodological Objectives Explained to Researchers Without Using Mathematical Equations	4
Pharmacogenetic Approaches to Optimize Bioequivalence Studies in Generic Drug Development	4
Efficacy and Safety of Annual Infusion of Zoledronic Acid and Weekly Oral Alendronate in the Treatment of Primary Osteoporosis: A Meta‐Analysis	4
Impaired Cardiometabolic Effects of Bromocriptine in Men With Early‐Onset Androgenic Alopecia	4
Obesity Considerations in Pediatric Drug Development, 2016–2021	4
Assessment of CYP‐Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients with Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	4
Genotype‐Guided Model for Prediction of Tacrolimus Initial Dosing After Lung Transplantation	4
Modeling of Pharmacokinetic Profiles of Insulin Aspart and Biphasic Insulin Aspart 30/70	4
Evaluating Tranexamic Acid Dosing Strategies for Postpartum Hemorrhage: A Population Pharmacokinetic Approach in Pregnant Individuals	4
From Fragmented Data to Integrated Drug Development in Asphyxiated Neonates Undergoing Therapeutic Hypothermia	4
Exogenous Melatonin and Sleep Quality: A Scoping Review of Systematic Reviews	4
Pharmacokinetic Characterization of Iopamidol and Iohexol for Optimizing Measured Glomerular Filtration Rate Assessment in Clinical Practice and Drug Development	4
	4
A Randomized Crossover Clinical Study to Assess the Effect of Oral Nicotine Pouches Used for Different Durations on Plasma Nicotine Pharmacokinetics in Healthy Oral Pouch Consumers	4
ChatGPT and Factual Knowledge Questions Regarding Clinical Pharmacy: Response to Letter to the Editor	4
Results of the ACTION‐Galactosemia Kids Study to Evaluate the Effects of Govorestat in Pediatric Patients with Classic Galactosemia	4
Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR‐T) Cell Therapy Targeting Delta‐Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (	4
Effect of Renal Impairment on the Pharmacokinetics of a Single Oral Dose of Danuglipron in Participants With Type 2 Diabetes	4
ACCP Position Statement on Unregulated Psychotropic Products	4
Pharmacokinetics and Safety of Imeglimin in Japanese Patients With Impaired Renal Function	4
Prescription of Oral Contraceptives by Licensed Pharmacists in the USA	4
Prediction of Pediatric Pharmacokinetics for CYP3A4 Metabolized Drugs: Comparison of the Performance of Two Hepatic Ontogeny Within a Physiologically Based Pharmacokinetic Model	4
Development of Risk Prediction Model for Grade 2 or Higher Hypocalcemia in Patients With Bone Metastasis Treated With Denosumab Plus Cholecalciferol (Vitamin D3)/Calcium Supplement	4
Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study	4
In Memoriam: Barry Dvorchik, BS, PhD, FCP	4
Population Pharmacokinetics and Exposure‐Response Relationships of Astegolimab in Patients With Severe Asthma	4
Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer	4